fda indications for semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Oral Semaglutide Gets FDA Approval
Description
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial @TheLancet @LillyTrials #Retatrutide
Choosing the right injection site for semaglutide affects how your body absorbs the medication and maintains steady therapeutic levels
In this study of 222,942 with #diabetes, semaglutide (Ozempic) was associated with a 32% lower risk of nicotine compared to other anti-diabetics
Yes the patent for Ozempics active ingredient (semaglutide) in India is set to expire in March 2026 (not March 2025)
Patients have a choice between multiple effective weight loss options for the first time in many years.
Learn how long it's safe, what happens if you stop, and how MeAgain helps you manage weight loss for the long haul.
